Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick
H I
HI
Upjohn Laboratories, Kalamazoo, Michigan 49001, USA.
Johnson
P D
PD
Howe
W J
WJ
Tomich
P K
PK
Chong
K T
KT
Watenpaugh
K D
KD
Janakiraman
M N
MN
Dolak
L A
LA
McGrath
J P
JP
Lynn
J C
JC
D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D004285:Dogs; D015195:Drug Design; D006678:HIV / Q000187:drug effects*; D016333:HIV Protease / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D015498:HIV-2 / Q000187:drug effects / Q000201:enzymology; D006860:Hydrogen Bonding; D008958:Models, Molecular; D009010:Monte Carlo Method; D011753:Pyrones / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D013449:Sulfonamides / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011753:Pyrones; D013449:Sulfonamides; C097589:U 103017; D016333:HIV Protease